Watson launches topical gel for overactive bladder

CORONA, Calif. Watson Pharmaceuticals has launched what it calls the first and only topical gel for overactive bladder.

The Corona, Calif.-based drug maker announced Thursday the launch of Gelnique (oxybutynin chloride) gel in the 10% strength for the treatment of OAB with symptoms of urinary incontinence, urgency and frequency.

“As the first and only topical gel for OAB, we believe that Gelnique provides physicians and their patients with an effective, easy first-line drug treatment option,” Watson CEO Paul Bisaro stated. “Because Gelnique is a first, we are launching our product with a unique promotional campaign, one that speaks to healthcare professionals and patients with language and images that are empowering.”